Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$7.09
+3.5%
$4.93
$2.23
$17.41
$319.91M2.832.57 million shs447,469 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$4.10
+5.7%
$3.00
$0.73
$4.41
$248.55M0.82286,838 shs253,670 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.34
+1.5%
$1.16
$0.83
$5.39
$81.86M1.13406,891 shs1.33 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.17
$1.78
$0.13
$3.29
$274.90M2.067.88 million shs2.86 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
0.00%-3.52%+52.22%+96.28%-54.90%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-0.51%+3.19%+35.66%+203.13%+66.52%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
+13.79%+16.81%+16.81%+7.32%-63.64%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-1.36%+9.60%+5.85%+1,128.77%+117.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.1396 of 5 stars
3.32.00.00.01.61.70.6
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.2833 of 5 stars
3.50.00.00.03.13.30.0
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.387 of 5 stars
3.32.00.00.03.30.80.6
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.0188 of 5 stars
3.30.00.00.01.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.64
Moderate Buy$30.40328.77% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.0046.34% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.60
Moderate Buy$8.67546.77% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.56
Moderate Buy$6.07179.57% Upside

Current Analyst Ratings Breakdown

Latest PYXS, GALT, VOR, and FDMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
8/18/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/14/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
8/14/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
8/14/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
8/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $38.00
8/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
8/1/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/29/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
7/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
7/3/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$40K8,277.58N/AN/A$9.01 per share0.79
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.86) per shareN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M5.15N/AN/A$1.41 per share0.95
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%N/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%N/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$13.66N/AN/AN/AN/AN/AN/AN/A

Latest PYXS, GALT, VOR, and FDMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16-$0.12+$0.04-$0.12N/AN/A
8/14/2025Q2 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.36-$0.30+$0.06-$0.30N/A$2.82 million
8/11/2025Q2 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
8.75
8.75
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
1.43
0.08
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
5.65
7.75
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
9.60%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
50.10%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.70 million42.22 millionOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
964.06 million31.97 millionOptionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6062.02 million55.44 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140126.68 million65.45 millionNot Optionable

Recent News About These Companies

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright
Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright
HC Wainwright Lowers Earnings Estimates for Vor Biopharma
Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright
Wedbush Comments on Vor Biopharma's Q3 Earnings (NYSE:VOR)
Vor Biopharma Announces Key Leadership Changes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$7.09 +0.24 (+3.50%)
Closing price 04:00 PM Eastern
Extended Trading
$7.10 +0.01 (+0.14%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$4.10 +0.22 (+5.67%)
Closing price 04:00 PM Eastern
Extended Trading
$4.02 -0.08 (-1.95%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.34 +0.02 (+1.52%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 +0.02 (+1.49%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.17 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.19 +0.02 (+1.15%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.